Chronic Myeloid Leukemia Coverage from Every Angle

Jerald Radich, MD, Named Inaugural Recipient of Kurt Enslein Endowed Chair at Fred Hutch

By: Sarah Jackson
Posted: Monday, August 26, 2019

Jerald Radich, MD, pioneering leukemia researcher and expert in molecular genetics, has been named the inaugural recipient of the Kurt Enslein Endowed Chair at Fred Hutchinson Cancer Research Center (Fred Hutch). John and Christine Enslein presented the Chair to Dr. Radich during a ceremony highlighting the Ensleins’ long history of support to Fred Hutch.

“Creating this new endowed chair is our way of paying back, considering the life-changing—and lifesaving—impact the Hutch has had on our lives,” said John Enslein. Mr. John Enslein was diagnosed with chronic myeloid leukemia in 1980 and received a bone marrow transplant at Fred Hutch.

This new endowed Chair will help advance Dr. Radich’s research of genes and other molecules that signal treatment response, progression, and relapse in patients with CML. He specializes in developing methods to improve the detection and treatment of chronic and acute myeloid leukemias.

“I am extremely grateful to the Ensleins for this fabulous gift to the Center and to patients with leukemia,” Dr. Radich noted. “It is hard to get [National Institutes of Health] funding for CML these days, and this gift will allow us to work on new ideas to further improve CML outcomes, both here and in low-resource areas.”

Dr. Radich developed a test for detecting rare leukemia cells in patients in remission to determine which patients are likely to relapse or to benefit from new targeted therapies. In addition to helping physicians tailor each patient’s care, the test promises to reduce the duration and cost of clinical trials. Dr. Radich also helped to develop a low-cost, paper-based method to diagnose CML in low-income countries.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.